David Sans
David Sans, FAARM, PhD, MBA, is an accomplished healthcare and finance leader with strategic experience in healthcare and life sciences.
David Sans, PhD, FAARM MBA, is a biotech and pharma executive with experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.
David Sans currently serves as Director of Healthcare at EF Hutton, where he oversees all Healthcare Transactions at EF Hutton spearheading and driving a wide range of industry transactions.
Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr. Medical Scientist at Novartis in Basel, Switzerland during the launch of Glivec® (imatinib), at ImClone Systems and Head of Corporate Development and David served as an Executive Officer at Mount Sinai Health Systems completing Business Development transactions with Philips, LabCorp, and Agilent. David is also a Board Member of the Lymphatic Education & Research Network in New York.
Biotech Advisor & Philantropist
David Sans is leverages his 20+ years of experience in the Healthcare and Finance industry to collaborate biotech companies and serve as advisor in healthcare-related non-for-profit organizations
Healthcare Expert
David Sans held executive positions in corporate development, investment and strategy at some of the leading investment banks, hospital systems and biotech companies. He’s attracted and inspired high-performance executive teams, restructured legacy retail and e-commerce groups, launched innovative and flexible store formats, and established deep relationships within the Wall Street analyst and investor community.
David Sans on Podcasts
David Sans is interviewed by Bant Breen’s UNCAGED Podcast
Carina Clingman interviews David Sans discussing the myths of micro-IPOs.
David Sans discussed the state of M&A activity surged in 2024 and why it’s expected to continue into 2025.